UroGen Pharma Statistics
Total Valuation
UroGen Pharma has a market cap or net worth of $519.02 million. The enterprise value is $402.23 million.
Important Dates
The next estimated earnings date is Monday, May 12, 2025, before market open.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
UroGen Pharma has 46.09 million shares outstanding. The number of shares has increased by 48.70% in one year.
| Current Share Class | 46.09M |
| Shares Outstanding | 46.09M |
| Shares Change (YoY) | +48.70% |
| Shares Change (QoQ) | +9.12% |
| Owned by Insiders (%) | 5.07% |
| Owned by Institutions (%) | 72.43% |
| Float | 36.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.34 |
| Forward PS | 3.97 |
| PB Ratio | -58.96 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.45 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.01
| Current Ratio | 6.01 |
| Quick Ratio | 5.59 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.64 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -25.78% |
| Return on Invested Capital (ROIC) | -79.15% |
| Return on Capital Employed (ROCE) | -39.91% |
| Revenue Per Employee | $384,672 |
| Profits Per Employee | -$539,889 |
| Employee Count | 235 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 1.19 |
Taxes
In the past 12 months, UroGen Pharma has paid $2.83 million in taxes.
| Income Tax | 2.83M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.35% in the last 52 weeks. The beta is 0.81, so UroGen Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.81 |
| 52-Week Price Change | -20.35% |
| 50-Day Moving Average | 10.49 |
| 200-Day Moving Average | 12.19 |
| Relative Strength Index (RSI) | 58.22 |
| Average Volume (20 Days) | 625,426 |
Short Selling Information
The latest short interest is 5.06 million, so 10.98% of the outstanding shares have been sold short.
| Short Interest | 5.06M |
| Short Previous Month | 5.65M |
| Short % of Shares Out | 10.98% |
| Short % of Float | 13.68% |
| Short Ratio (days to cover) | 10.68 |
Income Statement
In the last 12 months, UroGen Pharma had revenue of $90.40 million and -$126.87 million in losses. Loss per share was -$2.96.
| Revenue | 90.40M |
| Gross Profit | 81.52M |
| Operating Income | -95.68M |
| Pretax Income | -100.36M |
| Net Income | -126.87M |
| EBITDA | -95.35M |
| EBIT | -95.68M |
| Loss Per Share | -$2.96 |
Full Income StatementBalance Sheet
The company has $236.69 million in cash and $124.92 million in debt, giving a net cash position of $116.79 million or $2.53 per share.
| Cash & Cash Equivalents | 236.69M |
| Total Debt | 124.92M |
| Net Cash | 116.79M |
| Net Cash Per Share | $2.53 |
| Equity (Book Value) | -8.80M |
| Book Value Per Share | -0.21 |
| Working Capital | 230.19M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$96.77 million and capital expenditures -$295,000, giving a free cash flow of -$97.06 million.
| Operating Cash Flow | -96.77M |
| Capital Expenditures | -295,000 |
| Free Cash Flow | -97.06M |
| FCF Per Share | -$2.11 |
Full Cash Flow StatementMargins
Gross margin is 90.18%, with operating and profit margins of -105.85% and -140.35%.
| Gross Margin | 90.18% |
| Operating Margin | -105.85% |
| Pretax Margin | -137.22% |
| Profit Margin | -140.35% |
| EBITDA Margin | -105.48% |
| EBIT Margin | -105.85% |
| FCF Margin | n/a |
Dividends & Yields
UroGen Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -48.70% |
| Shareholder Yield | -48.70% |
| Earnings Yield | -24.44% |
| FCF Yield | -18.70% |
Analyst Forecast
The average price target for UroGen Pharma is $37.21, which is 230.46% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $37.21 |
| Price Target Difference | 230.46% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 57.42% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
UroGen Pharma has an Altman Z-Score of -2.68 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.68 |
| Piotroski F-Score | 3 |